20/20 Biolabs, Inc.

AIDX Nasdaq SEC CIK 1139685
Follow 20/20 Biolabs Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $380.2K −9% vs same quarter last year
Net income −$1.4M −66.6% vs same quarter last year
EPS, diluted −$0.12 +29.4% vs same quarter last year
Operating cash flow −$912.4K −136.6% vs same quarter last year
Revenue by quarter
$553.8K
$535.1K
$418K
$538.3K
$353.4K
$730.6K
$380.2K
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing